151 related articles for article (PubMed ID: 32061548)
21. Comprehensive genomic profiling of neuroendocrine bladder cancer pinpoints molecular origin and potential therapeutics.
Shen P; Jing Y; Zhang R; Cai MC; Ma P; Chen H; Zhuang G
Oncogene; 2018 May; 37(22):3039-3044. PubMed ID: 29535424
[TBL] [Abstract][Full Text] [Related]
22. The UBC-40 Urothelial Bladder Cancer cell line index: a genomic resource for functional studies.
Earl J; Rico D; Carrillo-de-Santa-Pau E; Rodríguez-Santiago B; Méndez-Pertuz M; Auer H; Gómez G; Grossman HB; Pisano DG; Schulz WA; Pérez-Jurado LA; Carrato A; Theodorescu D; Chanock S; Valencia A; Real FX
BMC Genomics; 2015 May; 16(1):403. PubMed ID: 25997541
[TBL] [Abstract][Full Text] [Related]
23. The evolution of bladder cancer genomics: What have we learned and how can we use it?
Audenet F; Attalla K; Sfakianos JP
Urol Oncol; 2018 Jul; 36(7):313-320. PubMed ID: 29573965
[TBL] [Abstract][Full Text] [Related]
24. Frequency and Nature of Genomic Alterations in ERBB2-Altered Urothelial Bladder Cancer.
Leary JB; Enright T; Bakaloudi DR; Basnet A; Bratslavsky G; Jacob J; Spiess PE; Li R; Necchi A; Kamat AM; Pavlick DC; Danziger N; Huang RSP; Lin DI; Cheng L; Ross J; Talukder R; Grivas P
Target Oncol; 2024 May; 19(3):447-458. PubMed ID: 38570422
[TBL] [Abstract][Full Text] [Related]
25. A TP53-Associated Immune Prognostic Signature for the Prediction of Overall Survival and Therapeutic Responses in Muscle-Invasive Bladder Cancer.
Wu X; Lv D; Cai C; Zhao Z; Wang M; Chen W; Liu Y
Front Immunol; 2020; 11():590618. PubMed ID: 33391264
[TBL] [Abstract][Full Text] [Related]
26. Discovery of TP53 splice variants in two novel papillary urothelial cancer cell lines.
Koch A; Hatina J; Rieder H; Seifert HH; Huckenbeck W; Jankowiak F; Florl AR; Stoehr R; Schulz WA
Cell Oncol (Dordr); 2012 Aug; 35(4):243-57. PubMed ID: 22669776
[TBL] [Abstract][Full Text] [Related]
27. Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome.
Allory Y; Beukers W; Sagrera A; Flández M; Marqués M; Márquez M; van der Keur KA; Dyrskjot L; Lurkin I; Vermeij M; Carrato A; Lloreta J; Lorente JA; Carrillo-de Santa Pau E; Masius RG; Kogevinas M; Steyerberg EW; van Tilborg AA; Abas C; Orntoft TF; Zuiverloon TC; Malats N; Zwarthoff EC; Real FX
Eur Urol; 2014 Feb; 65(2):360-6. PubMed ID: 24018021
[TBL] [Abstract][Full Text] [Related]
28. Recurrence pattern and TP53 mutation in upper urinary tract urothelial carcinoma.
Chen CH; Dickman KG; Huang CY; Shun CT; Tai HC; Huang KH; Wang SM; Lee YJ; Grollman AP; Pu YS
Oncotarget; 2016 Jul; 7(29):45225-45236. PubMed ID: 27286260
[TBL] [Abstract][Full Text] [Related]
29. TERT promoter mutations and TERT mRNA but not FGFR3 mutations are urinary biomarkers in Han Chinese patients with urothelial bladder cancer.
Wang K; Liu T; Liu C; Meng Y; Yuan X; Liu L; Ge N; Liu J; Wang C; Ren H; Yan K; Hu S; Xu Z; Fan Y; Xu D
Oncologist; 2015 Mar; 20(3):263-9. PubMed ID: 25657201
[TBL] [Abstract][Full Text] [Related]
30. Targeted sequencing of plasmacytoid urothelial carcinoma reveals frequent TERT promoter mutations.
Palsgrove DN; Taheri D; Springer SU; Cowan M; Guner G; Mendoza Rodriguez MA; Rodriguez Pena MDC; Wang Y; Kinde I; Ricardo BFP; Cunha I; Fujita K; Ertoy D; Kinzler KW; Bivalacqua TJ; Papadopoulos N; Vogelstein B; Netto GJ
Hum Pathol; 2019 Mar; 85():1-9. PubMed ID: 30447301
[TBL] [Abstract][Full Text] [Related]
31. Cancer type-dependent correlations between TP53 mutations and antitumor immunity.
Li L; Li M; Wang X
DNA Repair (Amst); 2020 Apr; 88():102785. PubMed ID: 32007736
[TBL] [Abstract][Full Text] [Related]
32. [Point somatic mutations in bladder cancer: key carcinogenesis events, diagnostic markers and therapeutic targets].
Mikhailenko DS; Nemtsova MV
Urologiia; 2016 Feb; (1):100-105. PubMed ID: 28247712
[TBL] [Abstract][Full Text] [Related]
33. Chromosomal imbalances in successive moments of human bladder urothelial carcinoma.
Nascimento e Pontes MG; da Silveira SM; Trindade Filho JC; Rogatto SR; Viana de Camargo JL
Urol Oncol; 2013 Aug; 31(6):827-35. PubMed ID: 21763161
[TBL] [Abstract][Full Text] [Related]
34. TERT promoter mutations in renal cell carcinomas and upper tract urothelial carcinomas.
Wang K; Liu T; Liu L; Liu J; Liu C; Wang C; Ge N; Ren H; Yan K; Hu S; Björkholm M; Fan Y; Xu D
Oncotarget; 2014 Apr; 5(7):1829-36. PubMed ID: 24742867
[TBL] [Abstract][Full Text] [Related]
35. Clinical correlation of extensive-stage small-cell lung cancer genomics.
Dowlati A; Lipka MB; McColl K; Dabir S; Behtaj M; Kresak A; Miron A; Yang M; Sharma N; Fu P; Wildey G
Ann Oncol; 2016 Apr; 27(4):642-7. PubMed ID: 26802149
[TBL] [Abstract][Full Text] [Related]
36. Genomic predictors of survival in patients with high-grade urothelial carcinoma of the bladder.
Kim PH; Cha EK; Sfakianos JP; Iyer G; Zabor EC; Scott SN; Ostrovnaya I; Ramirez R; Sun A; Shah R; Yee AM; Reuter VE; Bajorin DF; Rosenberg JE; Schultz N; Berger MF; Al-Ahmadie HA; Solit DB; Bochner BH
Eur Urol; 2015 Feb; 67(2):198-201. PubMed ID: 25092538
[TBL] [Abstract][Full Text] [Related]
37. Comprehensive Assessment of Immuno-oncology Biomarkers in Adenocarcinoma, Urothelial Carcinoma, and Squamous-cell Carcinoma of the Bladder.
Necchi A; Madison R; Raggi D; Jacob JM; Bratslavsky G; Shapiro O; Elvin JA; Vergilio JA; Killian JK; Ngo N; Ramkissoon S; Severson E; Hemmerich AC; Huang R; Ali SM; Chung JH; Reddy P; Miller VA; Schrock AB; Gay LM; Alexander BM; Grivas P; Ross JS
Eur Urol; 2020 Apr; 77(4):548-556. PubMed ID: 31959546
[TBL] [Abstract][Full Text] [Related]
38. NOTCH, ASCL1, p53 and RB alterations define an alternative pathway driving neuroendocrine and small cell lung carcinomas.
Meder L; König K; Ozretić L; Schultheis AM; Ueckeroth F; Ade CP; Albus K; Boehm D; Rommerscheidt-Fuss U; Florin A; Buhl T; Hartmann W; Wolf J; Merkelbach-Bruse S; Eilers M; Perner S; Heukamp LC; Buettner R
Int J Cancer; 2016 Feb; 138(4):927-38. PubMed ID: 26340530
[TBL] [Abstract][Full Text] [Related]
39. Genomic characterization of small cell carcinomas of the uterine cervix.
Schultheis AM; de Bruijn I; Selenica P; Macedo GS; da Silva EM; Piscuoglio S; Jungbluth AA; Park KJ; Klimstra DS; Wardelmann E; Hartmann W; Gerharz CD; von Petersdorff M; Buettner R; Reis-Filho JS; Weigelt B
Mol Oncol; 2022 Feb; 16(4):833-845. PubMed ID: 33830625
[TBL] [Abstract][Full Text] [Related]
40. Global gene expression profiling identifies ALDH2, CCNE1 and SMAD3 as potential prognostic markers in upper tract urothelial carcinoma.
Wu S; Chen J; Dong P; Zhang S; He Y; Sun L; Zhu J; Cheng Y; Li X; Tang A; Huang Y; Gui Y; Liu C; Yang G; Zhou F; Cai Z; Wang R
BMC Cancer; 2014 Nov; 14():836. PubMed ID: 25408144
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
